ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Lisata Therapeutics Inc

Lisata Therapeutics Inc (LSTA)

3.66
-0.04
(-1.08%)
At close: July 17 4:00PM
3.66
0.00
( 0.00% )
After Hours: 4:16PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
3.66
Bid
3.55
Ask
3.75
Volume
15,990
3.61 Day's Range 3.7999
1.95 52 Week Range 3.8699
Market Cap
Previous Close
3.70
Open
3.61
Last Trade
1
@
3.66
Last Trade Time
16:00:08
Financial Volume
$ 58,965
VWAP
3.6876
Average Volume (3m)
16,787
Shares Outstanding
8,307,433
Dividend Yield
-
PE Ratio
-1.48
Earnings Per Share (EPS)
-2.51
Revenue
-
Net Profit
-20.84M

About Lisata Therapeutics Inc

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases.

Sector
Health & Allied Services,nec
Industry
Insurance Carriers, Nec
Headquarters
Wilmington, Delaware, USA
Founded
2006
Lisata Therapeutics Inc is listed in the Health & Allied Services sector of the NASDAQ with ticker LSTA. The last closing price for Lisata Therapeutics was $3.70. Over the last year, Lisata Therapeutics shares have traded in a share price range of $ 1.95 to $ 3.8699.

Lisata Therapeutics currently has 8,307,433 shares outstanding. The market capitalization of Lisata Therapeutics is $30.74 million. Lisata Therapeutics has a price to earnings ratio (PE ratio) of -1.48.

LSTA Latest News

Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

Complete enrollment achieved nearly six months ahead of plan Top-line data now anticipated mid-2025 Addition of second-line cholangiocarcinoma arm to BOLSTER trial BASKING RIDGE, N.J., July 16...

Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model

BASKING RIDGE, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (β€œLisata” or the β€œCompany”), a clinical-stage pharmaceutical company developing innovative...

Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial

Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX based therapies in pancreatic, colon and appendiceal cancers BASKING RIDGE, N.J., June 13, 2024...

Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events

BASKING RIDGE, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (β€œLisata” or the β€œCompany”), a clinical-stage pharmaceutical company developing innovative...

Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided due to waiver BASKING RIDGE, N.J., May 20, 2024...

Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Seminal Phase 2b ASCEND trial top-line data expected in fourth quarter of 2024 Projected available cash to fund planned operations into early 2026 covering all studies through data Conference...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.257.331378299123.413.833.3171185583.63257913CS
40.3610.90909090913.33.833.22175583.50946384CS
120.932.60869565222.763.832.51167873.30081584CS
260.7425.34246575342.923.832.42146273.18632503CS
52-0.04-1.081081081083.73.86991.95199002.80954696CS
156-5.14-58.40909090918.89.381.95234883.85133116CS
260-5.14-58.40909090918.89.381.95234883.85133116CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SAISAI TECH Global Corporation
$ 1.22
(25.77%)
340.21k
ATXGAddentax Group Corporation
$ 0.9512
(21.06%)
1.52M
LUXHLuxUrban Hotels Inc
$ 0.233
(19.55%)
525.51k
BTOGBit Origin Ltd
$ 2.03
(8.56%)
2.2k
PETZTDH Holdings Inc
$ 1.38
(7.81%)
250
LESLLeslies Inc
$ 3.56
(-12.96%)
19.75k
SCNIScinai Immunotherapeutics Ltd
$ 4.01
(-10.54%)
2.44k
WIMIWiMi Hologram Cloud Inc
$ 0.96
(-9.41%)
144.58k
GDTCCytoMed Therapeutics Ltd
$ 2.16
(-8.47%)
1.83k
CETUCetus Capital Acquisition Corporation
$ 9.00
(-8.03%)
38.7k
NVDANVIDIA Corporation
$ 117.839
(0.01%)
3.71M
APVOAptevo Therapeutics Inc
$ 0.573
(-2.53%)
2.09M
BNDVanguard Total Bond Market
$ 73.0563
(-0.06%)
1.76M
KHCKraft Heinz Company
$ 33.90
(-0.03%)
1.58M
ATXGAddentax Group Corporation
$ 0.9512
(21.06%)
1.52M

LSTA Discussion

View Posts
TheFinalCD TheFinalCD 2 years ago
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169956690
πŸ‘οΈ0
subslover subslover 2 years ago
Never mind I see they did change the ticker and wow great job. CUDOS to you!
πŸ‘οΈ0
tedgoeseast tedgoeseast 2 years ago
The ticker it is LSTA get on etrade market castor that is what I am on
πŸ‘οΈ0
subslover subslover 2 years ago
Did they change the ticker?tia
πŸ‘οΈ0
tedgoeseast tedgoeseast 2 years ago
It going through the roof right now I left 5000 on the table who knew it was going over 9.00 wow volume at over 627000 now premarket
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 years ago
CONGRAT$
πŸ‘οΈ0
tedgoeseast tedgoeseast 2 years ago
It shows 615000 premarket on etrade market castor and it over 9.00 a share now wow
πŸ‘οΈ0
subslover subslover 2 years ago
But the stock shows 0 trades pre mkt???
πŸ‘οΈ0
tedgoeseast tedgoeseast 2 years ago
Clbs my second best play this week wow!! When everyone was saying it was tanking big time sold this morning for a nice Gain
πŸ‘οΈ0
tedgoeseast tedgoeseast 2 years ago
Wow I got up this morning and it was over 7.50 I called etrade and they put my sell order through I just made 2400.00 profit when everyone even moonmarket said it was a bad trade for him ,I bought at .40 yesterday 7.50is like selling it for .60 at the old share structure
πŸ‘οΈ0
subslover subslover 2 years ago
You're absolutely correct. I will keep this on watch.
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 years ago
lately everything is a pnd, they push it up too high and short it back

with some exceptions, that have a few day run
πŸ‘οΈ0
tedgoeseast tedgoeseast 2 years ago
I have been reading all about it on OTC site and stock twits I put a bid in for .385 just for the fun of it
πŸ‘οΈ0
PStockPickz PStockPickz 2 years ago
Merger news this morning mixed with the r/s is why I bought. Took loss and keeping it on radar for reversal
πŸ‘οΈ0
tedgoeseast tedgoeseast 2 years ago
YOU BOUGHT AT .63 IT WAS JUST AT .385
πŸ‘οΈ0
subslover subslover 2 years ago
Yea, nothing surprises me
πŸ‘οΈ0
PStockPickz PStockPickz 2 years ago
Looks like a group wacked out to chase another ticker
πŸ‘οΈ0
krisc62 krisc62 2 years ago
Watching for bounce from 52 WL
πŸ‘οΈ0
subslover subslover 2 years ago
I didn't get the memo. lol
πŸ‘οΈ0
PStockPickz PStockPickz 2 years ago
Maybe someone didn't get the memo that r/s plays are hot right now haha
πŸ‘οΈ0
PStockPickz PStockPickz 2 years ago
Snagged 63s
πŸ‘οΈ0
subslover subslover 2 years ago
LMAO!
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 years ago
LOLme2
πŸ‘οΈ0
subslover subslover 2 years ago
This is a very unusual year with all the R/S working out! Scratching my bald head!
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 years ago
post RS plays are HOT **CLBS* +Merger

adtx nrbo
πŸ‘οΈ0
PStockPickz PStockPickz 2 years ago
Yep double whammy r/s and merger. Surprised this isn't getting more attention
πŸ‘οΈ0
subslover subslover 2 years ago
Merger in progress
πŸ‘οΈ0
PStockPickz PStockPickz 2 years ago
R/s after the close. Could be another big runner
πŸ‘οΈ0
conix conix 3 years ago
Dawson James - Caladrius (CLBS) - Delays, Delays & delays + Burning Cash

Caladrius has fallen to $0.90 from $1.61 (2.15.21) when we wrote "Dam the Shareholders Full Speed Ahead", commenting on the highly dilutive capital raise. Revisiting the story, we see little progress. Caladrius reported 3Q21 results spending $7M in the quarter, steadily whittling down its $100M in cash balance but to what end? We note multiple delays across previously promoted programs such as CLI in Japan, now suspended.
Click here for the full report


HONDERA (CLBS12) – Suspended for CLI in Japan –This was planned as a small Phase 2 study, an interventional, open-label, proof-of-concept (POC) trial planned for two centers, but the company had problems finding patients, blaming COVID. Caladrius now says the program is suspended until a Japanese partner is identified. We remain skeptical and see this program as "dead."

XOWNA (CLBS16) – Enrollment has Slowed: The product is currently being evaluated in a P2b study in patients with CMD and without obstructive coronary artery disease. Patient enrollment is behind schedule, so the company has been expanding the number of sites and modifying the study protocol. These protocol amendments were implemented in the latter part of the quarter. We see these as "red flags."

Management was Pushing the CD34+ cells as a COVID Play – This appears to have fizzled out. Is anyone surprised? What's the Problem? On just about every level, we find management's explanations across multiple programs as lacking. Management seems to lack an understanding of 1. the competitive environment. Multiple off-the-shelf, allogeneic companies are already treating COVID patients but on ventilators and potentially earlier, and recent failures of other cell therapies in COVID due to improved standard of care. 2. For example, in COVID, using cells to ameliorate the after-effects of ventilator therapy for COVID patients is a great idea, BUT a) harvesting cells from these patients is not ideal; b) how do you measure how effective your treatment is? For NORDA, we see a POC trial as a $65M and multi-year investment. What size trial is needed to measure the effect versus standard of care? 3. Caladrius's autologous therapy is very late in the field.

Valuation. For Caladrius, we previously lowered our rating to Neutral from Buy (March 2020) and removed our price target. Our model uses our highest discount rate of 30% in our free cash flow to the Firm (FCFF), discounted EPS, and Sum of the Parts (SOP) models. Our models go out to 2029 and have been updated for the recent dilution. The company now has a negative enterprise value, but we believe that won't last as its likely management will now be on a spending spree. Spending on clinical trials that we feel go nowhere and or looking to make an acquisition. Our bottom-line concern is that Caladrius has, in our opinion, missed the window. Allogenic competitors are advancing now in heart failure, back pain, stroke, CLI, GvHD, and three companies are today treating COVID patients for ARDS

Risks to our thesis include the following: (1) commercial; (2) regulatory; (3) clinical; (4) manufacturing; (5) financial; (6) liability; and (7) intellectual property.

πŸ‘οΈ0
Roadtojourney Roadtojourney 3 years ago
Got new bagholders pos imo
πŸ‘οΈ0
slow_feet slow_feet 3 years ago
SI as of 2/12/21


2/12/2021 1,450,000 shares
1/29/2021 2,930,000 shares
1/15/2021 127,600 shares
12/31/2020 130,000 shares
12/15/2020 130,000 shares
πŸ‘οΈ0
slow_feet slow_feet 3 years ago
Four funds have new positions as of 2/12/21: https://whalewisdom.com/stock/nbs-2

πŸ‘οΈ0
CINCY_4MONEY CINCY_4MONEY 3 years ago
this stock is hot. they have a 9 a share 1st year target we will get there soon
πŸ‘οΈ0
slow_feet slow_feet 3 years ago
Opened a cr*p-load of April Calls in the AM.

C'mon 7!
πŸ‘οΈ0
ClayTrader ClayTrader 3 years ago
* * $CLBS Video Chart 01-20-2021 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
hotonthemoney hotonthemoney 3 years ago
Why Caladrius Biosciences Is Soaring Today
Why Caladrius Biosciences Is Soaring Today
πŸ‘οΈ0
hotonthemoney hotonthemoney 3 years ago
Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction
πŸ‘οΈ0
Carioca Carioca 3 years ago
weregoingherecscw
πŸ‘οΈ0
Ruffieruff Ruffieruff 3 years ago
Out as well. Pulled a profit so all good. Gltu
πŸ‘οΈ0
wickerman wickerman 3 years ago
$CLBS out core $4.05 will revisit..patience + DD forever

Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction

https://www.biospace.com/article/releases/caladrius-biosciences-treats-first-patient-in-the-phase-2b-freedom-trial-of-clbs16-for-the-treatment-of-coronary-microvascular-dysfunction/#:~:text=(Nasdaq%3A%20CLBS)%20(%E2%80%9C,dysfunction%20(%E2%80%9CCMD%E2%80%9D)%20at
πŸ‘οΈ0
Docstemcell2020 Docstemcell2020 3 years ago
Nice
πŸ‘οΈ0
AlphaStockNews AlphaStockNews 3 years ago
$CLBS is squeezing the shorts out of their positions following an announcement of a patient treated in a Phase 2b trial. https://cnafinance.com/clbs-stock-caladrius-biosciences-squeezes-shorts/
πŸ‘οΈ0
Ruffieruff Ruffieruff 3 years ago
14PT this morning. Huge move ahead.
πŸ‘οΈ0
Ruffieruff Ruffieruff 4 years ago
Figured you were long out. Now this bomb confirms it.
πŸ‘οΈ0
Ruffieruff Ruffieruff 4 years ago
Have you sold and moved on. Very quiet around here.
πŸ‘οΈ0
Ruffieruff Ruffieruff 4 years ago
Falling apart here. Are we do any updates anytime soon?
πŸ‘οΈ0
Ruffieruff Ruffieruff 4 years ago
How much patience does one need. We are going sideways and it’s not too much fun.
πŸ‘οΈ0
Swimmingly Swimmingly 4 years ago
Bought a few more cheapies today. Just have to be patient with this one.
πŸ‘οΈ0
Ruffieruff Ruffieruff 4 years ago
Unfortunately not looking so hot for us who bought in much higher.
πŸ‘οΈ0
Swimmingly Swimmingly 4 years ago
They sure are. GL
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock